CMBA
STRO icon

C.M. Bidwell & Associates’s Sutro Biopharma STRO Stock Holding History

C.M. Bidwell & Associates’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-172
Closed -$37K – 549
2020
Q4 		$37K Buy
+172
New +$28.5K 0.03% 305

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

C.M. Bidwell & Associates's STRO Position: Q1 2021 in Review

C.M. Bidwell & Associates sold out of Sutro Biopharma (STRO) in Q1 2021, closing a stake of 172 shares — an estimated $37K sold.

C.M. Bidwell & Associates first reported a position in STRO in Q4 2020 and held it in 1 quarter. The position peaked at $37K in Q4 2020. 138 funds tracked by Wall St. Rank hold STRO as of Q1 2021.

  • C.M. Bidwell & Associates reported no remaining Sutro Biopharma position as of Q1 2021 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 172 Sutro Biopharma shares in Q1 2021, an estimated $37K.
  • C.M. Bidwell & Associates first reported a position in Sutro Biopharma in Q4 2020 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Sutro Biopharma position peaked at $37K in Q4 2020.
  • 138 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2021.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2021, filed 14 May 2021.